Print this page    •   Back to Web version of article

U.S. News
Gilead and J&J Expand HIV Cocktail Partnership

November 16, 2011

Gilead Sciences Inc. and Johnson & Johnson's Tibotec division announced Tuesday they will work together to develop a new HIV pill that contains Tibotec's Prezista and Gilead's Emtriva. The tablet also will include Gilead's drug candidates cobicistat and GS 7340, which are not yet approved. Under the arrangement, Gilead will be responsible for manufacturing the drug, handling the regulatory process and selling the medication. Tibotec will retain co-marketing rights in some countries. The companies also partnered to develop Complera, which combines Gilead's Truvada with J&J's Edurant; it was approved in August.

Back to other news for November 2011

Excerpted from:
Boston Globe
11.15.2011; Associated Press

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.